PLEASANTON, Calif.--(BUSINESS WIRE)--Veeva Systems (NYSE:VEEV) today announced that Samsung BioLogics selected Veeva Vault QualityDocs to modernize quality document management. Vault QualityDocs enables Samsung BioLogics to provide transparency into content status and processes for internal and external users, partners, and suppliers worldwide. The company can also better scale its document control processes and ensure global alignment across the business.
Samsung BioLogics, based in South Korea, aimed to improve operational efficiency by giving global stakeholders easy and secure access to quality documents. External users can access Vault QualityDocs from anywhere, anytime in the cloud for greater agility. As a result, Vault QualityDocs will provide Samsung BioLogics with a single source of truth for quality documents.
“Vault QualityDocs will help support Samsung BioLogics’ strategic vision,” said Chie Soo Rhee, senior IT specialist of quality IT systems at Samsung BioLogics. “We look forward to partnering with Veeva to bring together our global quality processes.”
“With Vault QualityDocs, life sciences companies and contract manufacturing organizations can collaborate securely and gain greater transparency into global quality procedures,” said Chris Shim, country manager for Veeva Korea. “Samsung BioLogics is committed to the highest quality standards, and we’re honored to be chosen as a strategic technology partner.”
Vault QualityDocs is a modern, cloud-based application for GxP document control and management that delivers greater compliance, improved quality, and reduced operational overhead. It is part of Veeva Vault Quality Suite that unifies quality processes, document control, and training to drive global operational innovation.
For more on Veeva Vault QualityDocs, visit: veeva.com/QualityDocs
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Samsung BioLogics
Samsung BioLogics is a world-class contract manufacturing organization (CMO) committed to quality-driven manufacturing of biopharmaceutical products. Its customer-oriented business model supports both collaborative novel drug development and high-quality, fast-turnaround contract manufacturing partnerships. Samsung BioLogics aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency and ensure the highest quality products for the patient. For more information, please visit: www.samsungbiologics.com.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 625 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.